Is Tebentafusp-tebn included in medical insurance?

Patients with metastatic uveal melanoma have a poor prognosis and limited treatment options. Tebentafusp-tebn is the first drug in the new ImmTAC class of T-cell-directed therapies. Tebenforx has been shown to significantly improve overall survival and progression-free survival in a subset of patients with (HLA-A*02:01-positive) metastatic uveal melanoma. As with other forms of T cell-directed therapy, cytokine release syndrome continues to be a treatment-related adverse event in patients treated with tebenforx. The approval of the new drug tebenforx represents a major paradigm shift in the treatment of metastatic uveal melanoma.

Uveal melanoma is very rare. Tebenforsi was designated as an "orphan drug" (a drug for rare diseases) in the European Union on February 19, 2021. The active ingredient in tebentafusp is tebentafusp, a protein that recognizes and attaches to two targets at the same time: gp100 on the surface of uveal melanoma cancer cells and CD3 on the surface of T cells (which are part of the body's natural defenses). By linking these proteins, Tebenforx brings tumor cells and T cells into contact, triggering the T cells to kill the melanoma cells.

After a single dose, the Cmax and AUC0-7d of Tebenforx were increased from 20mcg to 68mcg in an approximate dose-proportional manner (0.3-1 times the approved recommended dose). In patients with metastatic uveal melanoma, the steady-state geometric mean (% CV) Cmax of tibenforx was 13 ng/mL (34.6%) and AUC0-7d was 4.6 ng.day/mL (23%) with no accumulation in patients with metastatic uveal melanoma at the approved recommended dose.

The original drug of Tibenforsi is not currently on the market in China, so it is not included in the medical insurance. After Tebenforx is approved for marketing, there may be less price and other related information. For more drug information and specific prices, please consult a medical consultant.